Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Around 3-7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyrosine kinase inhibitors (TKIs), such as crizotinib,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2021-02, Vol.12 (4), p.316-332
Hauptverfasser:	Carcereny, Enric, Fernández-Nistal, Alonso, López, Araceli, Montoto, Carmen, Naves, Andrea, Segú-Vergés, Cristina, Coma, Mireia, Jorba, Guillem, Oliva, Baldomero, Mas, Jose Manuel
Format:	Artikel
Sprache:	eng
Schlagworte:	Research Paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!